AOD9604 (Fragment 176-191)

Metabolic

aka Fragment 176-191 · hGH Frag 176-191 · AOD-9604

Compare

Formula

MW (Da)

Half-life

~30 min (SC)

Saves

Overview

AOD9604 (Fragment 176-191) is a synthetic analog derived from the C-terminal lipolytic region of human growth hormone, originally explored as an anti-obesity agent. Preclinical work supports adipose-centered lipolysis through β-adrenergic signaling, but human efficacy data have been inconsistent across development programs.

Mechanism

Preclinical studies link AOD9604 to lipolysis, fat oxidation, and β-adrenergic pathway interactions — especially β3-adrenergic receptor engagement in obese mice and rats. The fragment behaves differently from full-length hGH, with action concentrated on adipocyte metabolism rather than full endocrine GH replacement. Detailed human pharmacokinetics were not clearly retrieved in the source material.

0

Vendors

—

no vendors yet

Lowest price

—

Reported benefits

Modest weight loss in a 12-week obesity RCT

In one 12-week randomized clinical trial, subjects receiving 1 mg/day lost an average of 2.6 kg versus 0.8 kg on placebo — a small but measurable difference.

[aod9604-rct-pubmed]

clinical

Inconsistent efficacy across later development programs

Broader development summaries note that later studies — especially those incorporating intensive diet and exercise — were less convincing than the initial 12-week trial.

[aod9604-pmc-review]

clinical

Lipolytic and fat-oxidation effects in preclinical models

Chronic treatment reduced body-weight gain, increased fat oxidation, and stimulated lipolysis in rodent models, including 500 μg/kg/day orally and chronic IP dosing in obese mice.

[aod9604-preclinical]

preclinical

Reported side effects

Favorable short-term tolerability across oral dose levels
clinical
A dedicated tolerability paper reported no safety-related concerns across oral doses of 9, 27, and 54 mg.
Detailed adverse-event frequency tables not available
anecdotal
Available retrieved text did not include a detailed AE frequency table; incidence and severity beyond the overall favorable conclusion remain only partly specified.

Dosing notes

Human reports include 1 mg/day SC in a 12-week obesity RCT and oral tolerability studies at 9, 27, and 54 mg. Older preclinical work also used 500 μg/kg/day orally in rodents and chronic IP dosing in obese mice. No modern consensus clinical regimen exists.

Research use only. Information on this page is editorial reference, not medical or dosing advice. Always consult qualified medical guidance before use.

Storage

Peer-reviewed stability data were not retrieved. Practical storage guidance in the accessible literature is largely absent; general research-peptide practice is to store lyophilized material cold, dry, and protected from light, with frozen long-term storage preferred.

Vendors carrying AOD9604 (Fragment 176-191)

No approved vendors are listing this peptide yet. Check back later or browse the full vendor directory.

Discussion

Ask, answer, and vote on questions about AOD9604 (Fragment 176-191).

No questions yet. Be the first to ask.

References

[aod9604-preclinical]
AOD9604 preclinical lipolysis and fat-oxidation studies
Authors per PubMed entry · PubMed
Source
[aod9604-rct-pubmed]
Twelve-week randomized clinical trial of AOD9604 for obesity
Authors per PubMed entry · PubMed
Source
[aod9604-tolerability]
AOD9604 oral tolerability study (9, 27, 54 mg)
Authors per JOFEM entry · Journal of Endocrinology and Metabolism
Source
[aod9604-pmc-review]
AOD9604 development and efficacy review
Authors per PMC entry · PubMed Central
Source